Cytokinetics (CYTK) Misses Q3 EPS by 13c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($1.36), $0.13 worse than the analyst estimate of ($1.23). Revenue for the quarter came in at $463 thousand versus the consensus estimate of $1.21 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Etsy upgraded to buy at BofA on durable growth, buyback potential
- Nutanix (NTNX) PT Raised to $80 at Oppenheimer Into EPS
- BTCS posts $1.5M gross profit in Q2 2026, net loss widens
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
